Pharsight

Atrovent Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5676930 BOEHRINGER INGELHEIM Stabilized medicinal aerosol solution formulations
Oct, 2014

(9 years ago)

US5683677 BOEHRINGER INGELHEIM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US6739333 BOEHRINGER INGELHEIM Stainless steel canister for propellant-driven metering aerosols
May, 2020

(4 years ago)

US6983743 BOEHRINGER INGELHEIM Stainless steel canister for propellant-driven metering aerosols
May, 2020

(4 years ago)

US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(5 years from now)

Atrovent Hfa is owned by Boehringer Ingelheim.

Atrovent Hfa contains Ipratropium Bromide.

Atrovent Hfa has a total of 5 drug patents out of which 4 drug patents have expired.

Expired drug patents of Atrovent Hfa are:

  • US5676930
  • US5683677
  • US6739333
  • US6983743

Atrovent Hfa was authorised for market use on 27 November, 2004.

Atrovent Hfa is available in aerosol, metered;inhalation dosage forms.

The generics of Atrovent Hfa are possible to be released after 17 January, 2030.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ATROVENT HFA family patents

Family Patents